BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc., a leader in the development of therapies for immuno-oncology, announced today that Thomas W. Dubensky, Jr., Ph.D., chief scientific officer at the company, was a featured speaker at the Keystone Symposia conference on “The Modes of Action of Vaccine Adjuvants” being held in Seattle, WA this week where he presented preclinical data on the company’s cyclic-di-nucleotide (CDN) technology. The company is using CDNs to develop potent therapies that activate and enhance innate immunity, the body’s first line of defense against pathogens, which is emerging as an important mechanism in immuno-oncology applications.
Help employers find you! Check out all the jobs and post your resume.
